maintenance therapy

October 2, 2017

Tesaro Shares Multitude of Ovarian Cancer Treatment Findings at Madrid Conference

News

Half of ovarian cancer patients in a small study responded to a combination of Tesaro’s Zejula and Genentech’s Avastin, according to a presentation Tesaro made at the European Society of Medical Oncology (ESMO) 2017 ... Read more

September 1, 2017

Lynparza Maintenance Reduces Risk of Disease Progression in Advanced Ovarian Cancer Patients, SOLO-2 Trial Shows

News

Women with BRCA-mutated relapsed ovarian cancer whose tumors responded to platinum-based chemotherapy took significantly longer to see their disease progressing when given AstraZeneca’s Lynparza (olaparib) as a maintenance therapy, compared to placebo. In addition to ... Read more

August 19, 2017

Lynparza’s New Tablet Formulation Receives FDA Approval For Ovarian Cancer

News

A new formulation of Lynparza (olaparib) tablets received FDA approval to prevent disease progression and relapse in ovarian cancer patients. The new tablets allow patients previously taking the drug in capsule ... Read more

March 29, 2017March 29, 2017

FDA Approves Zejula as Maintenance Therapy for Ovarian, Other Women’s Cancers

News

The United States has approved Tesaro’s Zejula (niraparib) as a maintenance therapy for adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The Federal Drug Administration sign-off indicates that regulators ... Read more

March 1, 2017

Trial Therapy’s Potential to Prevent Ovarian Cancer Relapses Supported by Mouse Study

News

An investigational drug that boosts the response of natural killer (NK) cells — key players of first-line immune defenses — was recently shown to effectively decrease ovarian tumors in a ... Read more